Jinhao Pharmaceutical

Jinhao Pharmaceutical

About · Us

Company Profile

Development History

Corporate culture

Honors and Qualifications

Development History
2025
Chikungunya virus nucleic acid detection kits, Chikungunya virus IgM/IgG antibody detection kits, and Chikungunya virus antigen detection kits are supporting epidemic prevention and control efforts in Guangdong and other regions.
2022
Focus on developing applications and innovations for the Mycobacterium tuberculosis effector T-cell assay kit.
2019
Development and production of novel coronavirus (2019-nCoV) IgM/IgG antibody test kits and 2019-nCoV nucleic acid test kits.
2017
Participated in the Ministry of Science and Technology’s National Key Science and Technology Project of the 13th Five-Year Plan.
2015
Obtained 2010 Edition Pharmaceutical GMP Certification
2014
The HIV‑1 new‑infection ELISA kit has been approved for market release following evaluation by the U.S. CDC and the Chinese CDC.
2013
An RNA detection kit for the H7N9 avian influenza virus has been successfully developed.
2012
Participated in the Ministry of Science and Technology’s National Key Science and Technology Project during the 12th Five-Year Plan period. In the same year, it was included on the list of Beijing Municipal Engineering Laboratories.
2011
Through ISO/IEC 17025:2005 laboratory accreditation
2009
The RNA detection kit for Influenza A (H1N1) virus (2009) has obtained medical device registration approval.
2008
Biosafety reagent services for Olympic security
2007
The Hepatitis E Virus RNA Detection Kit (FQ‑PCR) has obtained a medical device registration certificate.
2001
Biological safety reagent successfully developed.
1995
Human Immunodeficiency Virus Antibody Diagnostic Kit (Enzyme-Linked Immunosorbent Assay)
Obtain a drug approval number
1993
Beijing Jinhao Pharmaceutical Co., Ltd. was established.